Pharma Intelligence is part of the Business Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ray Barlow, CEO of e-Therapeutics, talks to Scrip on the sidelines of the BIO-Europe partnering conference in Berlin, Germany, about network-driven discovery and its use by today's innovative pharma sector.
CEO of e-Therapeutics PLC, Ray Barlow, talks about working backwards to solve drug discovery and development problems, starting with the end target in mind and then thinking about how to apply new technologies to reach the bull's eye.
E-therapeutics' technology works by combining biological expertise and a powerful computer-based platform to create and analyze network models of disease to identify likely proteins that could be disrupted to treat a disease. It uses mathematical and data analysis techniques to augment and interrogate the vast amount of biological information currently available in both public and private databases.
With its technology, e-Therapeutics aims to shorten discovery times and reduce drug development costs.
Scrip & EBD Group
Biomedtracker: follow the drug development process
03 Apr 2017
Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.
Scrip: industry news and insights
Hong Kong is catching global attention as it plans to drastically change listing rules for biotech firms, potentially opening the way to both Chinese companies seeking public funding and international firms eyeing entry to China. A Shanghai biosimilars developer, among others, is now eyeing an offering.
Topics Policy and regulation
Scrip: industry news and insights
Mylan’s Symfi and Merck’s Zepatier gain preferred status on PBM's national preferred formulary for 2019. But more drugs are excluded from coverage – 242, up from 196 in 2018. <br />
Request a Trial
Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
Support the development and validation of your strategic plans and ensure commercial decisions are based on marketplace realities. Datamonitor Healthcare offers expert coverage of key diseases, treatments, companies, drugs, market access and market trends. Our primary research with physicians, payers, and KOLs (key opinion leaders) informs our treatment standards data and patient-based forecasts.
From discovery to patent expiry, and coverage spanning both ethical and generic drugs, Medtrack has you covered. Stay current on key financing, drug and biologics development and drug manufacturing information, all with a single tool.
Trialtrove is the go-to resource for clinical trial research. Easily track your competitors' clinical R&D activity with expert insights and continually monitored trials.
Looking for more products Product Finder
